3 Stocks Dragging In The Drugs Industry

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 153 points (-0.9%) at 17,738 as of Tuesday, May 3, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 534 issues advancing vs. 2,431 declining with 111 unchanged. The Drugs industry currently sits down 0.9% versus the S&P 500, which is down 0.9%. On the negative front, top decliners within the industry include Alnylam Pharmaceuticals ( ALNY), down 8.2%, Novo Nordisk A/S ( NVO), down 1.7%, AstraZeneca ( AZN), down 1.3%, Abbott Laboratories ( ABT), down 1.2% and Eli Lilly and ( LLY), down 0.8%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Amgen ( AMGN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Amgen is down $2.50 (-1.6%) to $156.49 on light volume. Thus far, 1.2 million shares of Amgen exchanged hands as compared to its average daily volume of 3.6 million shares. The stock has ranged in price between $156.00-$158.46 after having opened the day at $158.11 as compared to the previous trading day's close of $158.99. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. Amgen Inc., a biotechnology company, engages in discovering, developing, manufacturing, and delivering human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. Amgen has a market cap of $119.1 billion and is part of the health care sector. Shares are down 2.1% year-to-date as of the close of trading on Monday. Currently there are 6 analysts that rate Amgen a buy, no analysts rate it a sell, and 9 rate it a hold. TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels and good cash flow from operations. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. 2. As of noon trading, Celgene ( CELG) is down $1.61 (-1.5%) to $103.36 on light volume. Thus far, 1.7 million shares of Celgene exchanged hands as compared to its average daily volume of 5.7 million shares. The stock has ranged in price between $102.54-$104.50 after having opened the day at $103.60 as compared to the previous trading day's close of $104.97. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. Celgene has a market cap of $80.8 billion and is part of the health care sector. Shares are down 12.3% year-to-date as of the close of trading on Monday. Currently there are 14 analysts that rate Celgene a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, growth in earnings per share and expanding profit margins. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Celgene Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. 1. As of noon trading, Gilead ( GILD) is down $1.20 (-1.4%) to $87.80 on average volume. Thus far, 5.2 million shares of Gilead exchanged hands as compared to its average daily volume of 12.2 million shares. The stock has ranged in price between $87.00-$89.12 after having opened the day at $88.69 as compared to the previous trading day's close of $89.00. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $120.6 billion and is part of the health care sector. Shares are down 12.1% year-to-date as of the close of trading on Monday. Currently there are 11 analysts that rate Gilead a buy, no analysts rate it a sell, and 7 rate it a hold. TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, attractive valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Gilead Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).